Case number# PHEH2015US017174, is an initial report received on 01 Sep 2015 from a consumer (patient) via a 
patient oriented program (POP ID: POP00002581; Gilenya Go Program). This report refers to an adult female 
patient.
The patient's medical history and concomitant medications were not reported. The patient received Gilenya 
(fingolimod) capsule (lot number: F0010; expiration date: Jul 2016) for the treatment of multiple sclerosis from 21 
Jun 2015 at a dose of 0.5 mg, QD (oral). 
The patient reported that, on an unknown date, her lymphocytes had gone down extremely low (lymphocyte count 
decreased) and doctor was monitoring her for that. On an unknown date (reported as from about 2 weeks ago as of
this report), the patient was developing some personality changes that were not like her and also her memory was 
getting worse (memory impairment). On an unknown date (reported as from about a week ago as of this report), 
the patient was developing headaches. The patient reported that physician did not think it was progressive 
multifocal leukoencephalopathy (PML), but they were checking her for that, they were just being cautious; physician
thought it was unlikely that the patient had PML. The patient reported that they repeated the John Cunningham 
virus (JCV) titer, it was mildly positive. The patient underwent some blood work and was going to do a magnetic 
resonance imagining (MRI) which was going to happen tomorrow (as of this report). Treatment with Gilenya was 
ongoing at the time of this report. The outcome of the events was reported as condition deteriorated. 
These events were not assessed for the seriousness by the consumer. The causality of the events was not 
reported.